 |
153 Diseases |  |
74 Trials |
|
74 Trials |  |
10107 News |  |
| «12...74757677787980818283848586» |
- | Trial primary completion date: Corticosteroids for Children With Febrile Urinary Tract Infections (clinicaltrials.gov) - May 3, 2017
P3, N=390, Recruiting, Sponsor: University of Pittsburgh
Trial primary completion date: Mar 2017 --> Mar 2018
- | prednisolone / Generic mfg.
New P2/3 trial: A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma (clinicaltrials.gov) - Apr 27, 2017
P2/3, N=30, Not yet recruiting, Sponsor: Postgraduate Institute of Medical Education and Research
- | itraconazole / Generic mfg.
Trial primary completion date: A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis (clinicaltrials.gov) - Apr 27, 2017
P2/3, N=150, Recruiting, Sponsor: Postgraduate Institute of Medical Education and Research
Trial primary completion date: Mar 2017 --> Mar 2018 Trial primary completion date: Mar 2017 --> Jun 2017
- ||| tacrolimus intravenous / Generic mfg.
Enrollment closed, Combination therapy: T-OPTIMUM: A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome (clinicaltrials.gov) - Apr 25, 2017
P4, N=144, Active, not recruiting, Sponsor: Astellas Pharma Korea, Inc.
Trial primary completion date: Mar 2017 --> Jun 2017 Recruiting --> Active, not recruiting
- avalotcagene ontaparvovec (DTX301) / Ultragenyx
Enrollment closed: CAPtivate: Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset Ornithine Transcarbamylase (OTC) Deficiency (clinicaltrials.gov) - Apr 21, 2017
P1/2, N=9, Active, not recruiting, Sponsor: Dimension Therapeutics
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | prednisolone / Generic mfg.
Enrollment closed: Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants (clinicaltrials.gov) - Apr 21, 2017
P2, N=120, Active, not recruiting, Sponsor: Prof. Dominique de Quervain, MD
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| thioguanine / Generic mfg.
New P2/3 trial, IO biomarker: Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma (clinicaltrials.gov) - Apr 17, 2017
P2/3, N=1000, Recruiting, Sponsor: St. Jude Children's Research Hospital
- | Trial primary completion date: DETECT: Descemet Endothelial Thickness Comparison Trial (clinicaltrials.gov) - Apr 17, 2017
P4, N=50, Active, not recruiting, Sponsor: Winston Chamberlain, MD, PhD
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2018 --> Oct 2018
- | prednisolone / Generic mfg., vincristine / Generic mfg.
Journal: A retrospective analysis of combination chemotherapy consisting cyclophosphamide, vincristine, prednisolone and procarbazine (C-MOPP) for pretreated aggressive non-Hodgkin lymphoma. (Pubmed Central) - Apr 13, 2017
Efficacy and toxicity were in line with other recent studies involving new agents, given that the subjects mainly consisted of elderly outpatients. These data provide a rationale for the use of C-MOPP as a current control treatment arm when the response to new cancer therapy agents is evaluated.
- | AZD4017 / AstraZeneca
New P2 trial: TICSI: Targeting Iatrogenic Cushing's Syndrome With 11?-hydroxysteroid Dehydrogenase Type 1 Inhibition (clinicaltrials.gov) - Apr 13, 2017
P2, N=32, Not yet recruiting, Sponsor: University of Oxford
- | Enrollment open: Steroids in Children Hospitalized With Asthma (clinicaltrials.gov) - Apr 4, 2017
P4, N=300, Recruiting, Sponsor: University of Florida
These data provide a rationale for the use of C-MOPP as a current control treatment arm when the response to new cancer therapy agents is evaluated. Not yet recruiting --> Recruiting
- | Enrollment closed: DETECT: Descemet Endothelial Thickness Comparison Trial (clinicaltrials.gov) - Mar 31, 2017
P4, N=50, Active, not recruiting, Sponsor: Winston Chamberlain, MD, PhD
Not yet recruiting --> Recruiting Enrolling by invitation --> Active, not recruiting
- |||||| Nucala (mepolizumab) / GSK
Enrollment open: Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) (clinicaltrials.gov) - Mar 14, 2017
P3, N=120, Recruiting, Sponsor: GlaxoSmithKline
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||||| montelukast / Generic mfg.
Trial completion: Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, Montelukast Sodium) for Acute Asthma (MK-0476-288) (clinicaltrials.gov) - Mar 12, 2017
P3, N=650, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting No longer recruiting --> Completed
- | prednisolone / Generic mfg., tacrolimus intravenous / Generic mfg., tacrolimus oral / Generic mfg.
Trial primary completion date: MinTAC: Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease (clinicaltrials.gov) - Mar 6, 2017
P4, N=52, Recruiting, Sponsor: Imperial College Healthcare NHS Trust
No longer recruiting --> Completed Trial primary completion date: Oct 2016 --> Dec 2018
- | prednisolone / Generic mfg.
Journal: Drug-induced liver injury caused by iodine-131. (Pubmed Central) - Mar 4, 2017
DILI caused by iodine-131 was suspected. Oral prednisolone was started at 30 mg/day, to which the patient responded well.
- | mycophenolate mofetil / Generic mfg., azathioprine / Generic mfg.
Trial completion: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis (clinicaltrials.gov) - Mar 3, 2017
P2, N=32, Completed, Sponsor: Genovate Biotechnology Co., Ltd.,
Oral prednisolone was started at 30 mg/day, to which the patient responded well. Active, not recruiting --> Completed
- | prednisolone / Generic mfg., entecavir / Generic mfg.
Journal: Hepatitis B viremia manifesting as polyarteritis nodosa and secondary membranous nephropathy. (Pubmed Central) - Feb 16, 2017
Prednisolone (60 mg/day), plasmapheresis (5 courses) and entecavir (0.5 mg/ every second day) were started...So patient was considered to have an association of classic PAN and MN, both related to HBV. Patient responded to combined treatment of steroid, plasmapheresis and nucleoside analogue.
- betamethasone/dexchlorpheniramine maleate / Generic mfg., prednisolone / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Cutaneous Rash Treatment (clinicaltrials.gov) - Feb 16, 2017
P3, N=17, Terminated, Sponsor: EMS
Patient responded to combined treatment of steroid, plasmapheresis and nucleoside analogue. N=140 --> 17 | Recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Aug 2016; By sponsor decision due to difficulty of recruitment
- |||||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment open, Trial primary completion date, BRCA Biomarker, PARP Biomarker: Study of Olaparib (Lynparza (clinicaltrials.gov) - Feb 15, 2017
P3, N=340, Recruiting, Sponsor: AstraZeneca
N=140 --> 17 | Recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Aug 2016; By sponsor decision due to difficulty of recruitment Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2021 --> Jan 2020
- || Remicade (infliximab) / J&J
Trial primary completion date: Top-down Infliximab Study in Kids With Crohn's Disease (clinicaltrials.gov) - Feb 9, 2017
P4, N=100, Enrolling by invitation, Sponsor: Erasmus Medical Center
Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2021 --> Jan 2020 Trial primary completion date: Dec 2018 --> Dec 2019
- Trial initiation date: Steroids in Children Hospitalized With Asthma (clinicaltrials.gov) - Feb 6, 2017
P4, N=300, Not yet recruiting, Sponsor: University of Florida
Trial primary completion date: Dec 2018 --> Dec 2019 Initiation date: Jul 2016 --> Feb 2017
- |||||||||| Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
New P2/3 trial: Ibrutinib for untreated mantle cell lymphoma (EUDRACT) - Jan 24, 2017
P2/3, N=400, Ongoing, Sponsor: Plymouth Hospitals NHS Trust
- abiraterone acetate / Generic mfg.
Phase classification: Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer (clinicaltrials.gov) - Jan 24, 2017
P=N/A, N=0, Approved for marketing, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Initiation date: Jul 2016 --> Feb 2017 Phase classification: P3 --> P=N/A
- prednisolone / Generic mfg.
Enrollment closed, Trial primary completion date: Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy (clinicaltrials.gov) - Jan 19, 2017
P2, N=24, Active, not recruiting, Sponsor: Washington University School of Medicine
Phase classification: P3 --> P=N/A Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Mar 2017
- || tacrolimus intravenous / Generic mfg.
Trial primary completion date, Combination therapy: T-OPTIMUM: A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome (clinicaltrials.gov) - Jan 17, 2017
P4, N=152, Recruiting, Sponsor: Astellas Pharma Korea, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Mar 2017 Trial primary completion date: Oct 2016 --> Sep 2017
- avalotcagene ontaparvovec (DTX301) / Ultragenyx
Enrollment open: CAPtivate: Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset Ornithine Transcarbamylase (OTC) Deficiency (clinicaltrials.gov) - Jan 11, 2017
P1/2, N=9, Recruiting, Sponsor: Dimension Therapeutics
Trial primary completion date: Oct 2016 --> Sep 2017 Not yet recruiting --> Recruiting
- avalotcagene ontaparvovec (DTX301) / Ultragenyx
New P1/2 trial: CAPtivate: Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset Ornithine Transcarbamylase (OTC) Deficiency (clinicaltrials.gov) - Dec 13, 2016
P1/2, N=9, Not yet recruiting, Sponsor: Dimension Therapeutics
- prednisolone / Generic mfg.
Enrollment open: Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants (clinicaltrials.gov) - Dec 1, 2016
P2, N=120, Recruiting, Sponsor: Prof. Dominique de Quervain, MD
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Tazverik (tazemetostat) / Ipsen, Rituxan (rituximab) / Roche
Enrollment open, Trial primary completion date: Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy (clinicaltrials.gov) - Nov 17, 2016
P1/2, N=133, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2017 --> Jun 2017
- | mycophenolate mofetil / Generic mfg., azathioprine / Generic mfg.
New P2 trial: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis (clinicaltrials.gov) - Oct 30, 2016
P2, N=30, Active, not recruiting, Sponsor: Genovate Biotechnology Co., Ltd.,
- |||| Aliqopa (copanlisib) / Bayer
Trial primary completion date, Combination therapy: CHRONOS-4: Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (clinicaltrials.gov) - Oct 27, 2016
P3, N=676, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2017 --> Jun 2017 Trial primary completion date: Mar 2021 --> Sep 2021
- prednisolone / Generic mfg.
New trial: Prednisolone Improves IVF Outcomes in Men With Anti-sperm Antibodies (clinicaltrials.gov) - Oct 16, 2016
P=N/A, N=241, Completed, Sponsor: Barz IVF Center for Infertility Treatment and Embryo Research
- | prednisolone / Generic mfg.
New P2 trial: Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants (clinicaltrials.gov) - Oct 16, 2016
P2, N=120, Not yet recruiting, Sponsor: Prof. Dominique de Quervain, MD
- prednisolone / Generic mfg., levofloxacin / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date: Effects of Oral Steroid in Mycoplasma Pneumoniae Pneumonia (clinicaltrials.gov) - Oct 14, 2016
P4, N=80, Recruiting, Sponsor: Seoul National University Hospital
Trial primary completion date: Mar 2021 --> Sep 2021 Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Jun 2016 | Trial primary completion date: Dec 2016 --> Dec 2017
- | mizacorat (AZD9567) / AstraZeneca
Trial completion, Enrollment change: A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567. (clinicaltrials.gov) - Sep 30, 2016
P1, N=48, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Jun 2016 | Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed | N=72 --> 48
- ||||| Xofigo (radium Ra-223 dichloride) / Bayer
Enrollment closed: ERA 223: Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms (clinicaltrials.gov) - Sep 23, 2016
P3, N=806, Active, not recruiting, Sponsor: Bayer
Active, not recruiting --> Completed | N=72 --> 48 Recruiting --> Active, not recruiting
- | prednisolone / Generic mfg., betamethasone / Generic mfg.
New P4 trial: Acute Unilateral Vestibulopathy and Corticosteroid Treatment (clinicaltrials.gov) - Sep 22, 2016
P4, N=180, Recruiting, Sponsor: Lund University
- ||| hydrocortisone / Generic mfg.
Enrollment closed, Trial primary completion date: Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus (clinicaltrials.gov) - Sep 19, 2016
P2, N=104, Active, not recruiting, Sponsor: US Oncology Research
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Feb 2017
- || mizacorat (AZD9567) / AstraZeneca
Enrollment closed: A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567. (clinicaltrials.gov) - Sep 8, 2016
P1, N=72, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Feb 2017 Recruiting --> Active, not recruiting
- prednisolone / Generic mfg.
Trial suspension: chILD-EU_EAA: Stop Exogenous Allergic Alveolitis (EAA) in Childhood (clinicaltrials.gov) - Sep 8, 2016
P2, N=45, Suspended, Sponsor: Matthias Griese
Recruiting --> Active, not recruiting Recruiting --> Suspended
- ||||| Tazverik (tazemetostat) / Ipsen, Rituxan (rituximab) / Roche
New P1/2 trial: Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy (clinicaltrials.gov) - Sep 5, 2016
P1/2, N=133, Not yet recruiting, Sponsor: The Lymphoma Academic Research Organisation
- prednisolone / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Enrollment open: Cortico-cop: Corticosteroid Reduction in COPD (clinicaltrials.gov) - Sep 3, 2016
P4, N=318, Recruiting, Sponsor: Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Recruiting --> Suspended Not yet recruiting --> Recruiting
- | prednisolone / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
New P4 trial: Cortico-cop: Corticosteroid Reduction in COPD (clinicaltrials.gov) - Aug 5, 2016
P4, N=318, Not yet recruiting, Sponsor: Chronic Obstructive Pulmonary Disease Trial Network, Denmark
- |||||||||| Nucala (mepolizumab) / GSK
New P3 trial: Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) (clinicaltrials.gov) - Jul 19, 2016
P3, N=120, Not yet recruiting, Sponsor: GlaxoSmithKline
- | prednisolone / Generic mfg.
Trial initiation date, Trial primary completion date, Head-to-Head: PULPISOLONE: Efficacy of Oral Prednisolone on Pain Reduction in Emergency Care of Acute Irreversible Pulpitis (clinicaltrials.gov) - Jul 19, 2016
P3, N=120, Not yet recruiting, Sponsor: University Hospital, Bordeaux
Not yet recruiting --> Recruiting Initiation date: Feb 2016 --> Oct 2016 | Trial primary completion date: Dec 2018 --> Aug 2019
- | prednisolone / Generic mfg.
New P4 trial: Oral Glucocorticoids Effect on Post Endodontic Pain (clinicaltrials.gov) - Jun 30, 2016
P4, N=400, Completed, Sponsor: Cairo University
- || mizacorat (AZD9567) / AstraZeneca
Trial primary completion date: A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567. (clinicaltrials.gov) - Jun 15, 2016
P1, N=72, Recruiting, Sponsor: AstraZeneca
Initiation date: Feb 2016 --> Oct 2016 | Trial primary completion date: Dec 2018 --> Aug 2019 Trial primary completion date: Apr 2016 --> Sep 2016
- | New P4 trial: Steroids in Children Hospitalized With Asthma (clinicaltrials.gov) - May 23, 2016
P4, N=300, Not yet recruiting, Sponsor: University of Florida
- | Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
New P2 trial: Pegfilgrastim in Patients With Alcoholic Hepatitis (clinicaltrials.gov) - May 18, 2016
P2, N=78, Not yet recruiting, Sponsor: Timothy Morgan, MD